Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial

References

• Finnish Cancer Registry [Internet]. Helsinki: Institute for Statistical and Epidemiological Cancer Research; 2010. [cited 2010 Oct 2]. Available from: http://www.cancerregistry.fi
   Google Scholar
• Mäklin S, Rissanen P. Cost of cancer – Treatment and productivity costs in 1996–2004 and forecast to year 2015. Finnish Cancer Organizations Publication no. 67. Helsinki, Finland: Finnish Cancer Organization; 2006. Finnish.
   Google Scholar
• Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, . Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: A nationwide population based study. Clin Cancer Res 2003;9:923–30.
   PubMed Web of Science ®Google Scholar
• Owens MA, Horten BC, Da Silva MM. Her2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemisty in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004;5:63–9.
   PubMedGoogle Scholar
• Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, . Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707–12.
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, . Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659–72.
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, . Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673–84.
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Rolski J, . Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 Study (abstract 62). Cancer Res 2009;69:500s.
   Google Scholar
• Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, . HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2007; 369(9555):29–36.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, . FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809–20.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, . Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer Trial. J Clin Oncol 2009;27:5685–92.
   PubMed Web of Science ®Google Scholar
• The Synergism Or Long Duration (SOLD) Study. ClinicalTrials.gov Identifier: NCT00593697.
   Google Scholar
• Chan AL, Leung HW, Lu CL, Lin SJ. Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: A systematic review. Ann Pharmacother 2009;43:296–303.
   PubMed Web of Science ®Google Scholar
• Reed SD, Schulman KA. Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer. Value Health 2009;12:637–40.
   PubMedGoogle Scholar
• Dedes KJ, Szucs TD, Imesch P, Fedier A, Fehr MK, Fink D. Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: A model-based analysis of the HERA and FinHer trial. Ann Oncol 2007;18:1493–9.
   PubMed Web of Science ®Google Scholar
• Millar JA, Millward MJ. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: A lifetime model. Pharmacoeconomics 2007;25:429–42.
   PubMed Web of Science ®Google Scholar
• Neyt M, Huybrechts M, Hulstaert F, Vrijens F, Ramaekers D. Trastuzumab in early stage breast cancer: A cost-effectiveness analysis for Belgium. Health Policy 2008;87:146–59.
   PubMed Web of Science ®Google Scholar
• Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998;13:397–409.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–92.
   PubMed Web of Science ®Google Scholar
• Statistics Finland. Statistical yearbook of Finland 2008 – The official statistics of Finland. Helsinki: Statistics Finland; 2008.
   Google Scholar
• Lidgren M, Wilking N, Jönsson B, Rehnberg C. Health related quality of life in different states of breast cancer. Qual Life Res 2007;16:1073–81.
   PubMed Web of Science ®Google Scholar
• Purmonen T, Auvinen PK, Martikainen JA. Budget impact analysis of trastuzumab in early breast cancer: A hospital district perspective. Int J Technol Assess Health Care 2010;26:163–9.
   PubMed Web of Science ®Google Scholar
• Clarke M, Collins R, Darby S, Davies C, Evans E, Godwin J. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365(9472):1687–717.
   PubMedGoogle Scholar
• Hall PS, Hulme C, McCabe C, Oluboyede Y, Round J, Cameron DA. Updated cost-effectiveness analysis of trastuzumab for early breast cancer: A UK perspective considering long-term toxicity and pattern of recurrence. Leeds Institute of Health Sciences, Working Paper. June 2010.
   Google Scholar
• Norum J, Olsen JA, Wist EA, Lønning PE. Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta Oncol 2007;46:153–64.
   PubMed Web of Science ®Google Scholar
• Wilking U, Jönsson B, Wilking N, Bergh J. Trastuzumab use in breast cancer patients in the six Health Care Regions in Sweden. Acta Oncol 2010;49:844–50.
   PubMed Web of Science ®Google Scholar
• Lidgren M, Jönsson B, Rehnberg C, Willking N, Bergh J. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann Oncol 2008;19:487–95.
   PubMed Web of Science ®Google Scholar
• Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility. J Clin Oncol 2007;25:3525–33.
   PubMed Web of Science ®Google Scholar
• Drummond M, Evans B, LeLorier J, Karakiewicz P, Martin D, Tugwell P, . Evidence and values: Requirements for public reimbursement of drugs for rare diseases – a case study in oncology. Can J Clin Pharmacol 2009;16:e273–81.
   Google Scholar
• Metcalfe S, Evans J, Priest G. PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer. N Z Med J 2007;120(1256):U2593.
   Google Scholar
• Herceptin now an election issue. [cited 2010 Nov 2]. Available from: http://www.stuff.co.nz/national/herceptin-debate/569826/Herceptin-now-an-election-issue
   Google Scholar
• The Pharmaceutical Management Agency of New Zealand [Internet]. [updated 2011 Jan 26; cited 2010 Nov 2]. Wellington: PHARMAC; 2008. Available from: http://www.pharmac.govt.nz/herceptin#gov
   Google Scholar